W
William Small
Researcher at Loyola University Chicago
Publications - 423
Citations - 15241
William Small is an academic researcher from Loyola University Chicago. The author has contributed to research in topics: Radiation therapy & Brachytherapy. The author has an hindex of 56, co-authored 396 publications receiving 12744 citations. Previous affiliations of William Small include University of Hong Kong & University of Chicago.
Papers
More filters
Journal ArticleDOI
Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies.
Charles A. Staley,Wayne Harris,Jerome C. Landry,William Small,David A. Kooby,Theresa W. Gillespie,Mary Meyers,Kapil N. Bhalla +7 more
TL;DR: The authors developed a strategy that includes a novel approach of induction full-dose chemotherapy followed by traditional chemoradiation as a neoadjuvant therapy for pancreatic cancer that reports the results of a phase I/II trial of gemcitabine, cisplatin, and 5-FU for patients with advanced gastrointestinal malignancies.
Journal ArticleDOI
Salvage treatment in recurrent endometrial cancer of the pelvis and peritoneal cavity.
Lindsey A. McAlarnen,Kelly Ryan,William Adams,Adam Gliniewicz,Abigail Winder,Margaret Liotta,Ronald K. Potkul,William Small,Matthew M. Harkenrider +8 more
TL;DR: No significant association of a definitive salvage regimen for recurrent endometrial cancer of the pelvis and peritoneal cavity is found and Aggressive use of multimodality therapy with surgery followed by tumor-directed radiotherapy and chemotherapy offers potentially curative therapy for these patients.
Journal ArticleDOI
S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): A secondary analysis of RTOG 9704.
Margaret A. Tempero,Kathryn Winter,Grace E. Kim,Sanjay Kakar,T. S. Hyun,William F. Regine,Rex B. Mowat,Kevin P. Charpentier,William Small,Chandan Guha,David K. Chang,Andrew V. Biankin,Rtog +12 more
TL;DR: Failure to validate S100A2 as a prognostic marker in RTOG 9704 may be a function of small number of archival samples available for analysis, and comparison to the historical retrospective untreated cohort suggests that S 100A2 may also be a predictive biomarker for response to treatment.
Journal ArticleDOI
Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy?
W. Ross Green,Lara Hathout,Atif J. Khan,Mohamed A. Elshaikh,Sushil Beriwal,William Small,Omar Mahmoud +6 more
TL;DR: The analysis suggests that surgery (followed by adjuvant RT or CRT) and definitive radiotherapy (with or without chemotherapy) result in equivalent survival.